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Abstract 
Cultured skin fibroblasts from four patients with Leigh syndrome and cytochrome c oxidase deficiency were studied. Mitochondrial 
DNA (mtDNA) analysis excluded large-scale deletions and known point mutations associated with Leigh syndrome. The COX activities 
were reduced to ! 8-44% of healthy probands, when measured in the presence of laurylmaltoside, COX activity from patients was shown 
to be more temperature sensitive than COX activity from control cells. In order to determine the subunit composition of COX 
immunoblotting studies were performed using mono- and polyclonal antibodies to distinct subunits. A monoclonal antibody to subunit IV 
crossreacted with two unknown proteins of higher apparent molecular weight in mitochondria from three patients, but not in mitochondria 
from control and the fourth patient. Quantification of immunoreactivity revealed a decrease of subunits II/ I I I  and IV parallel to the 
determined enzyme activity. In contrast, a variable amount of subunit VIIa (and/or VIIb) was found in mitochondria from different 
patients. The results indicate a defective COX holoenzyme complex in patients with Leigh syndrome and suggest different molecular 
origins of the defect. 
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1. Introduction 
The pathologic entity of Leigh syndrome, a rare and 
fatal mitochondrial encephalopathy, is characterized by 
progressive psychomotor retardation and brainstem abnor- 
malies. The diagnosis is based on neuropathological 
changes revealed by cranial MRI and usually confirmed by 
autopsy [1,2]. The syndrome was shown to be clinically 
and causually heterogeneous. Biochemically a variety of 
enzyme defects are related to Leigh syndrome, all leading 
to respiratory deficiency and thus reduced energy supply. 
Defective enzymatic activity was described for the 
pyruvate dehydrogenase complex [3-5], cytochrome c oxi- 
dase (COX) [2,6,7], ATP-synthase [8-10], NADH 
dehydrogenase [ 11,12] and biotinidase [ 13]. Therefore, the 
molecular defect of the syndrome can be located either in 
the mitochondrial or in the nuclear genome. Mutations at 
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position 8993 in the ATPase-6 gene of the mitochondrial 
DNA (mtDNA) [8-10], originally described for NARP 
(Neurogenetic muscle weakness, Ataxia, and Retinitis Pig- 
mentosa) [14], and the mutation at position 8344 in the 
tRNA Ly~ of mtDNA, characteristic for MERRF (Myoclonic 
Epilepsy with Ragged Red Fibers) have also been found in 
patients with Leigh syndrome [15]. The syndrome thus can 
be maternally inherited. 
Other investigations have shown a nuclear origin of the 
defect [16] with an autosomal recessive [7,11] or X-chro- 
mosomal recessive inheritance [5]. Only in the latter case 
the mutation could be identified; it is located in the Ela 
subunit of the pyruvate dehydrogenase complex. The most 
abundant form of the Leigh syndrome is associated with 
COX deficiency [2,7,17]. 
Human COX, the terminal enzyme of the mitochondrial 
respiratory chain, is composed of three mitochondrial- 
coded and ten nuclear-coded subunits, Two nuclear-coded 
subunits occur in tissue-specific soforms (Via and VIIa) 
[ 18,19]. Recently the X-ray structures of COX from bovine 
heart [20] and Paracoccus denitrificans [21] have been 
elucidated. The mechanism of assembly and regulation of 
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the holoenzyme complex, however, still remains largely 
unknown. 
Leigh syndrome with associated COX deficiency re- 
veals decreased enzyme activities in most tissues [7,22-24]. 
Therefore investigations on the molecular basis of the 
defect have been frequently done with cultured skin fibrob- 
lasts. Glerum et al. [25,26] and Robinson et al. [27] 
observed changed kinetics, whereas Zimmermann and 
Kadenbach [28] found decreased enzyme stability and 
modified subunit ratios in the COX complex from patients. 
In the present paper a comprehensive biochemical analysis 
of COX in fibroblasts from four further patients with 
Leigh syndrome is described. 
tions, l0 ~g DNA for each lane were separated onto a 
0.6% agarose gel and transferred to nylon membranes 
(Hybond). As mitochondrial probe a 974 bp fragment from 
the D-loop region was used, which was obtained by PCR 
using the primer: GCCCGAATGATATTTCC (forward) 
and CCACctgcagCCGGCCCATAACACTTGGG 
(reverse). 
Screening for the nucleotide (nt)8344 MERRF mutation 
was performed using the mispairing PCR described by 
Seibel et al. [31] and for the nt 8993 NARP mutation as 
described by Tatuch et al. [8], but using the following 
primers TACCCTATAGCACCCCCTCTA (forward) and 
GTGTGAAAACGTAGGCTTG (reverse). 
2. Materials and methods 
2.1. Patients and cell cultures 
The patients, all female, had a similar clinical presenta- 
tion of Leigh syndrome which was previously described 
for patients 3 and 4 (patients 2 and 4, respectively of Ref. 
[29]. After a normal pregnancy and development during 
infancy neurological regression became apparent in early 
childhood. The patients manifested progressive hypotonia, 
ataxia, generalized weakness and lactic acidosis. The diag- 
nosis was based on characteristic neuroradiologic findings 
of Leigh syndrome [1,2]. 
Fibroblasts from patient 1 (at the age of 2 yr and 10 
ruth) were grown from biopsied skin specimens (taken 
with informed parental consent). Skin fibroblasts from 
patients with Leigh syndrome (patients 2-4, ages 2 yr 4 
ruth, 1 yr 9 mth and 3 yr, respectively) were obtained from 
Dr. Zabon, Lyon. Control fibroblasts from healthy probands 
(1 and 3 yr old) were provided by Dr. Zabot and Prof. Dr. 
Schachtschabel, Marburg. 
Respiratory chain activities were determined on muscle 
biopsies but revealed only deficiency of complex IV. 
Pyruvate dehydrogenase d ficiency was excluded on mus- 
cle biopsy studies for patient 1 and on fibroblasts for all 
patients. 
Skin fibroblasts from patients and controls were grown 
in 250 ml flasks in RPMI 1640 medium with Glutamax !
(Gibco BRL) supplemented with 10% fetal calf serum as 
described [28]. For the following experiments fibroblast 
cultures at passages 15-25 were used. 
2.2. Mitochondrial DNA analysis 
DNA was extracted from skin fibroblasts by standard 
techniques [30] and was used as a template for PCR or was 
digested with restriction enzymes (Bam HI, PvuII) in 
order to linearize mtDNA. 
Southern blot analysis was performed using the ECL 
direct nucleic acid labelling and detection system 
(Amersham Buchler) according to manufacturer's instruc- 
2.3. Preparation and purification of antibodies 
Polyclonal antibodies against subunits II/III, Va and 
COX holoenzyme from human heart were raised in rabbits 
as described previously [32]. Affinity purification of anti- 
bodies to subunit I I/ I I I  from the antiserum to these sub- 
units was performed with purified subunits II/III. About 1 
mg of isolated COX from human heart was separated by 
preparative SDS-PAGE (18 cm gel length), blotted onto 
nitrocellulose, and stained with Amido Black. 2-3 mm 
wide strips of subunits II/I I I  were cut out and blocked for 
2 h at room temperature with Nitro Block (Serva, Heidel- 
berg) in PBS. The nitrocellulose membrane snips were 
incubated for 2 h at room temperature under shaking in a 5 
ml plastic syringe with 0.5 ml antiserum to subunit II/III 
in TSE (10 mM Tris/HCl, pH 7.5, 150 mM NaCI, 5 mM 
EDTA). After 3 times washing with TSE the bound anti- 
body was eluted twice with 2 ml 0.2 M glycine/HCl, pH 
2.0, by rotating the syringe for 2 rain. The antibody 
extracts were immediately neutralized to pH 7.4 with 2 M 
Tris base, pH 8,0. 
Monoclonal antibodies to subunits IV, and VlIa + VIIb 
were prepared as described by Schneyder et al. [33]. 
2.4. Preparation of mitochondria and cell extracts ,for 
Western blots 
Mitochondria were isolated as described by Moreadith 
and Fiskum [34]. This method involved washing of 
trypsinized fibroblasts from ten 250 ml culture flasks with 
PBS, followed by washing with 250 mM sucrose, 20 mM 
Tris/HCl, pH 7.3, 2 mM EDTA. After adjustment to 
1-2. 108 cells/ml the suspension was incubated under 
shaking in the same medium containing 0.15% digitonin 
for 10 rain at 20°C. 
Total cell extracts were prepared by washing the conflu- 
ent grown cells of a 250 ml culture flask with PBS, 
counting of the cell number, and digestion of the sedi- 
mented cells for one hour at room temperature with 100 
i~1/106 cells of 4% SDS, 2 mM EDTA, 0.1% Prefabloc 
SC (Merck, Darmstadt). After centrifugation the super- 
natant was precipitated with trichloroacetic acid, and dis- 
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solved in 0.4% SDS, 500 mM Tris/C1, pH 7.4, 8 M urea, 
10% glycerol and 5% 2-mercaptoethanol. 
2.5. Immunodetection 
Mitochondria or cell extracts were separated by SDS- 
PAGE [33] and blotted onto nitrocellulose (Schleicher and 
Schiill, Dassel) or PVDF-membranes (Immobilon transfer 
membranes from Millipore, Eschborn). After blocking, the 
membranes were incubated with the indicated primary 
antibody for 1 h at room temperature. Detection was 
performed either by a chromatogenic method as described 
by Possekel et al. [35] or by chemoluminescence using the 
'Western Light Kit' (from Tropix, Serva, Heidelberg) 
according to manufacturer's instructions. Chemolumines- 
cence was detected for the indicated time with a Kodak 
X-Omat AR film. 
2.6. Preparation of  cell extracts fi~r actit:i~ determinations 
Trypsinized fibroblasts from a 250 ml culture flask 
were washed twice with PBS, repeatedly frozen and 
thawed, suspended in 250 mM sucrose, 20 mM Mops, pH 
7.4. and adjusted to 1 mg protein/ml. After addition of 
0.05% digitonin the suspension was shaken at room tem- 
perature for 5 min, washed with 250 mM sucrose, 20 mM 
Mops, pH 7.4, 1 mM EDTA and sonicated in a bath type 
sonifier. 
2. Z Assay of  COX actit,i O, 
COX activity in cell extracts was measured spectropho- 
tometrically at 550 nm and 25°C according to Cooperstein 
and Lazarow [36] in 50 mM KPi, pH 7.4, 1 mM EDTA, 8 
p~M ferrocytochrome c and 0.1% laurylmaltoside or 1% 
Tween 80, as indicated. COX activity in muscle biopsy 
(patient 1) was determined as described by Bonne et al. 
[37]. 
2.8. Quantitation of  Western blots" 
Quantitative image analysis was performed on a Macin- 
tosh LC II computer using the public domain NIH Image 
program written by Wayne Rasband at the U.S. National 
Institutes of Health with the macros Gel_Plotting_ 
Andreas.txt (written by Andreas Becker and available from 
http: / /www.chemie.uni -marburg.de/~ b cker/  
macrodoc.htm. 
3. Results 
Southern blot analysis of isolated DNA from all studied 
cell lines excluded large-scale deletions of mtDNA (such 
as the 'common deletion'). Furthermore screening for point 
mutations at nt 8993 in the ATPase 6 gene of mtDNA, 
characteristic for NARP, and at nt 8344 in the tRNA Ly~ 
gene of mtDNA, characteristic for the MERRF disease. 
were negative. 
The COX activity of skin fibroblasts from patients with 
Leigh syndrome and from control probands was measured 
spectrophotometrically in the presence of laurylmaltoside 
and compared with the activity determined in muscle 
biopsies, as shown in Table 1. The percentage decreased 
activities from control values are not the same in skeletal 
muscle and fibroblasts of the same patient, but a decreased 
COX activity is seen in skeletal muscle (7-30%) and 
fibroblasts (18-44%) of all patients. 
The activity of COX was also measured with Tween 20 
as detergent and compared with the activity measured with 
laurylmaltoside (Fig. 1). In control fibroblasts the absolute 
COX activity was 3 times lower with Tween 20 than with 
laurylmaltoside. In patient fibroblasts, however, the per- 
centage of decreased activity, as related to control, was 
lower with laurylmaltoside, down to half of the value 
measured with Tween 20. 
An indication for a decreased stability of the COX 
complex in fibroblasts from patients with Leigh syndrome 
follows from Fig. 2. Incubation at 43°C leads to a more 
rapid inhibition of COX activity in cell extracts from 
patients than from control. Interestingly, the inhibition of 
activity is faster in patient 1 with 18% of normal COX 
activity than in patient 2 with 44% COX activity (see 
Table 1). 
In order to determine the stoichiometries of COX sub- 
units in the enzyme complex from patients, we applied 
Table l 
COX activity in fibroblasts from four patients with Leigh's syndrome 
Tissue Control Patient 1 Patient 2 Patient 3 Patient 4
Skeletal muscle ~' 
% from control < 30% 7% 10% 12~ 
Fibroblasts b 167 30 74 33 35 
% from control 100% 18% 44% 20% 21 c~ 
For comparison the enzyme activity (% of control) in biopsied skeletal muscle of the patients i also given. 
Enzyme activities in muscle homogenates were obtained from Professor B. Echenne, CHU, Montpellier (patient 2) and from Collombet et al. [29] 
(patients 3and 4). 
b COX activities were measured spectrophotometrically in fibroblast extracts inthe presence oflaurylmaltoside and are presented in nmol ferrocytochrome 
c oxidized rain- i mg protein- i. The values represent averages from 3-5 individual determinations. 
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Fig. 1. Comparison of COX activities of fibroblast extracts measured 
either with Tween 20 or with laurylmaltoside ( *). The average activity of 
control fibroblasts was 167 nmol cytochrome c rain-i mg protein-t in 
the presence of laurylmaltoside, and 63 in the presence of Tween 20 
(average of 3-5 determinations). The activity was measured spectropho- 
tometrically in 50 mM KPi, pH 7.4, 1 mM EDTA, 8 ~M cytochrome c, 
and 1% Tween 20 or 0.1% laurylmaltoside, as indicated. C, control 
fibroblasts; P1-P4, fibroblasts from patients 1-4. 
mono-  and polyclonal antibodies. The reactivities of the 
antibodies are shown in the Western blot of  Fig. 3 with 
isolated COX from human heart. Polyclonal antibodies to 
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Fig. 2. Thermostability of COX in fibroblast extracts from control and 
patients with Leigh syndrome. Cell extracts were incubated at 43°C in 
250 mM sucrose, 20 mM Mops, pH 7.2 for the indicated times, and the 
activity of COX was determined in the presence of laurylmaltoside as 
described in Section 2. 
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Fig. 3. Immunoreactivity of mono- and polyclonal antibodies with COX 
from human heart. Isolated COX from human heart was separated by 
SDS-PAGE, blotted onto nitrocellusose and incubated with the antisera 
against polypeptides of COX from human heart or with hybridoma cell 
culture supernatants (monoclonal antibodies against polypeptides of COX 
from bovine heart). Lane 1 and 6, antiserum to holoenzyme; lane 2, 
antiserum to subunits II +III; lane 3, supernatant to subunit IV; lane 4, 
antiserum to subunit Va; lane 5, supernatant to subunits VIIa+VIIb. 
subunits II (+  III), Va and to the holoenzyme, and mono- 
clonal antibodies to subunits IV and VI Iab were applied. 
Both, immunoblott ing and EL ISA  studies with isolated 
mitochondria from fibroblasts were performed, but im- 
munoblott ing data were shown to be more reliable. 
In a first approach, the polyclonal antibody against the 
holoenzyme from human heart reacting with COX subunits 
II, IV, V and VI revealed a general reduction of both, 
mitochondrial and nuclear-coded subunits in mitochondria 
from patient cells (not shown). Further analyses were 
performed with antibodies to specific COX subunits. 
Fig. 4 presents the immunoreact ivity of  mitochondria 
from control and from patients fibroblasts with monoclonal  
antibodies to subunits IV and VIIab. Again, subunit IV is 
less intensively stained in mitochondria from patients than 
from control, although the double amount of  mitochondrial 
protein was applied. Surprisingly, two additional bands of  
higher molecular weight were stained with the antibody to 
subunit IV (verif ied in experiments using only this anti- 
body). One additional band is seen with mitochondria from 
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Fig. 4. Immunodetection f COX subunits IV and VIIa in isolated 
mitochondria of fibroblasts from control and patients with Leigh syn- 
drome with monoclonal ntibodies. The Western blot was performed with 
30 p~g (control) or 60 Ixg (patients) of mitochondrial protein added to 
each lane of the SDS-polyacrylamide g l. As a reference (R) isolated 
COX from human heart was used (black lines). The antibodies bound to 
the PVDF-membrane were visualized by the 'Western light' method. In 
the upper part of the figure the film was illuminated for 90 min, in the 
lower part overnight. 
patients 2-4 and another, with even higher apparent size, 
only with mitochondria from patient 3. The identity of 
these proteins, not detected in mitochondria from control 
fibroblasts, however, could not be determined. 
The monoclonal antibody to subunits VIIab reacted 
only with mitochondria from patient 2, indicating the 
presence of more than 50% of these subunits compared to 
control mitochondria. After overnight exposition of the 
blot some reactivity was also seen with mitochondria from 
control and from the other patient fibroblasts (lower part of 
Fig. 4). The ratio of subunits IV/VIIab is much higher in 
mitochondria of patient 2 than of control, indicating an 
abnormal subunit composition of complex IV. 
In order to correlate quantitatively the amount of sub- 
unit IV with the COX activity, we performed Western 
blots with total cell extracts from patient cells and variable 
amounts from control cells (not shown). Again the western 
light method was used but under these conditions (see 
Section 2) the additional bands above subunit IV were 
absent, apparently due to their insolubility under the acid 
conditions of cell solubilization. The chemoluminescence 
intensities of the blot with total cell extracts and of another 
blot with isolated mitochondria were quantitated with an 
NIH image program (see methods). Table 2 compares the 
percentage of COX activity and of the amounts of subunit 
IV in mitochondria nd fibroblast extracts from patients 
with that of control. A correlation between the decreased 
amount of subunit IV in mitochondria or cell extracts and 
the activity of COX in patients, as compared to control, is 
found. A different picture is obtained when the correlation 
is done with COX activities measured in the presence of 
Tween 20 instead of laurylmaltoside (Fig. 1). 
The relationship between activity and amount of im- 
munoreactivity was also determined for the mitochon- 
drial-coded subunit II/III. The Western blot of mito- 
chondria from patients 1-3 and from control fibroblasts 
with the affinity-purified antibody to subunit I I/ I I I  (see 
methods), however, shows three instead of a single band 
(Fig. 5). While the upper band at position of subunit I I/ I I I  
has the strongest intensity in control mitochondria (C), it 
has the weakest intensity in mitochondria from patients 
1-3. Since the isolated COX, used for affinity-purification 
of the antibody, was highly purified (see lane R of Fig. 5), 
we conclude that the two lower bands represent degrada- 
tion products of subunit II/III. This degradation could be 
due to lysosomal proteases during permeabilization of 
fibroblasts. Incubation of fibroblasts for 10 min at 20°C 
with digitonin (see Section 2) permeabilizes cholesterol- 
containing membranes like the plasma, lysosomal and 
outer mitochondrial membrane. 
Table 2 
Parallel decrease of COX activity and the amount of subunit IV, quantitated from Western blots with isolated mitochondria (Fig. 4) and cell extracts (Fig. 
5) from patients with Leigh syndrome, as compared to control fibroblasts (100%) 
Patient l Patient 2 Patient 3 Patient 4 
COX activity ~ 18% 44% 20% 21% 
Subunit IV in cell extracts b 15% 33% 18% n.d. 
Subunit IV in mitochondria b 18% 37% 19% 21% 
The activity of COX, presented as percentage from control, was determined spectrophotometrically in fibroblast extracts in the presence of 
laurylmaltoside (Table l). In control fibroblasts the average activity was 167 nmol ferrocytochrome c rain-t mg protein-i 
b The quantitative analysis of immunodetected subunit IV was performed using an NIH-Image program, n.d., not determined. 
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Fig. 5. Immunodetection f COX subunit II in mitochondria of fibroblasts 
from control and patients with Leigh syndrome. 100 Ixg of mitochondrial 
protein from control (C) and patient fibroblasts (PI-P3) were separated 
by SDS-PAGE, blotted onto nitrocellulose, incubated with affinity-puri- 
fied polyclonal antibodies to human COX subunit II, and detected by the 
'Western light' method. As a reference Coomassie-blue stained COX 
from human heart is shown (R). 
The data of Fig. 5 suggest hat degradation of subunit 
II/I I I  is elevated in fibroblasts from patients with Leigh 
syndrome. Quantification of the three bands, immunode- 
tected with the antibody to subunit II/I I I  (Fig. 5), revealed 
corresponding intensities for subunits I I / I I! and IV in 
fibroblasts from control and patients 1-3 (not shown). 
These data indicate that COX in fibroblasts of the investi- 
gated patients contains subunits I I/ I I I  and IV in normal 
proportions but variable amounts of the smaller subunits 
(e.g., VIIab). 
4. Discussion 
Two results of this study indicate a diminished stability 
of the COX complex in fibroblasts from patients with 
Leigh syndrome with associated COX deficiency. First, 
COX from patients is more rapidly inactivated uring 
incubation at 43°C, and second, the percentage enzymatic 
activity of COX from patients, as compared to control, is 
lower when measured in the presence of laurylmaltoside 
than in the presence of Tween 20. The latter effect can be 
explained by the specific properties of the two detergents 
used. Tween 20 maintains COX in the dimeric and mem- 
brane-bound state [38], while laurylmaltoside dissociates 
COX into monomers [39]. Furthermore laurylmaltoside 
was shown to partly dissociate COX subunits accompanied 
by stimulation of activity [40-42]. The selective dissocia- 
tion of subunit VIb by laurylmaltoside l d to increased 
COX activity, and thus suggested a negative regulation of 
enzyme activity by this subunit [41]. 
The results hown in Fig. 1 confirm previous data about 
the inhibition of COX from patients fibroblasts in the 
presence of laurylmaltoside and low phosphate concentra- 
tions as compared to stimulation of COX activity in con- 
trol fibroblasts under these conditions [28]. A diminished 
COX stability was also concluded from other studies [43]. 
By quantitative immunodensitometric analysis we fur- 
thermore demonstrated a ecreased amount of a mitochon- 
drial-coded (subunit II) as well as a nuclear-coded subunit 
(IV), which parallels the decreased enzymatic activity, 
measured in the presence of laurylmaltoside. Thus, the 
functional enzyme core is assembled, but its steady state 
level is decreased. A normal biosynthesis of mitochondrial 
and nuclear-coded COX subunits in fibroblasts from two 
patients with Leigh syndrome was described by Hayasaka 
et al. [44]. Therefore an elevated rate of degradation could 
explain the lowered amount of enzyme. The enhanced 
proteolytic leavage of subunit II in permeabilized fibrob- 
lasts from patients (Fig. 5) supports this assumption. 
The parallel decrease of mitochondrial and nuclear- 
coded COX subunits in patients with COX-associated Leigh 
syndrome have been described repeatedly [2,17,26,44,45]. 
However, this decrease does not occur precisely similar for 
all subunits, but a variable immunoreaction of subunits 
VIIa/VIIb in comparison to the enzymatic activity was 
found in fibroblasts from different patients (Fig. 4). Thus, 
the subunit ratio IV/VIIab is not constant in fibroblasts 
from the different patients. A non-parallel decrease of 
mitochondrial and nuclear-coded subunits was also de- 
scribed by Zimmermann and Kadenbach [28]. Therefore 
the COX deficiency in Leigh syndrome is not solely due to 
a decreased amount, but in addition to a changed subunit 
composition of the complex. This could result in decreased 
stability and thus defective regulation and/or enhanced 
degradation of the enzyme complex. 
With the monoclonal antibody to subunit IV we ob- 
served two new crossreacting proteins of higher apparent 
molecular weight in mitochondria from patients 2-4. One 
protein in patients 2 and 4 could represent the unprocessed 
precursor of subunit IV, while the other unknown protein 
of even larger size was only found in patient 3. These 
results suggest a different molecular basis of COX defi- 
ciency in patient 1, patients 2 and 4, and patient 3. 
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